LAG3 and triple-negative breast carcinoma: In order to validate our hypothesis (that LAG-3 expression is associated with better outcome, especially in triple-negative breast cancer) we validated our results using an independent and larger cohort of triple-negative breast cancer samples with publicly available gene-expression data and existing clinical and follow-up data [24].